Search - tctmd.com

Displaying 1 - 20 of 23

Sort: Relevancy | Date

News Conference News TCT 2021

TAVI Edges Out Surgery in 2-Year Costs for Low-risk Patients: PARTNER 3

Yael L. Maxwell

November 05, 2021

Presentation TCT 2021

SURTAVI: Five-Year Results From a Randomized Trial of TAVR vs. SAVR in Patients at Intermediate Surgical Risk

Presenter: Nicolas Van Mieghem

November 05, 2021

News Conference News TCT 2021

SURTAVI: Self-Expanding TAVI Valve Holds Up vs SAVR Through 5 Years

Todd Neale

November 05, 2021

News Opinion Editor's Corner TCT 2021

In-Person and Online: TCT to Showcase Imaging, Valves, DCBs, and More

Shelley Wood

November 01, 2021

Presentation TCT 2020

TCT 125: TAVR with a Supra-Annular, Self-Expandable Valve in Intermediate Risk Patients: Follow-Up From the SURTAVI Randomized Trial and Continued Access Registry

Presenter: Paul Mahoney

October 14, 2020

Presentation TCT 2018

SURTAVI: Two-Year Complete Results From a Randomized Trial of a Self-Expanding Transcatheter Heart Valve vs Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Intermediate Surgical Risk

Presenter: Horst Sievert, Brian K. Whisenant, Jeffrey J. Popma

September 23, 2018

Presentation TCT 2017

SURTAVI Trial Critique and Unanswered Questions

Presenter: David J. Moliterno, Vinod H. Thourani, E. Murat Tuzcu

November 01, 2017

Presentation TCT 2017

SURTAVI: Topline Findings and Practice Implications

Presenter: David J. Moliterno, Vinod H. Thourani, Nicolas M. Van Mieghem

November 01, 2017

Presentation TCT 2017

TCT 107: Transcatheter Aortic Valve Replacement With a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients: Complete 1-Year Outcomes From the SURTAVI Trial

Presenter: Steven R. Bailey, Patrick W. Serruys, Nicolas M. Van Mieghem

November 01, 2017

Presentation TCT 2017

TCT 39: Clinical Outcomes in SURTAVI Based on Revascularization Stratification

Presenter: Jean-Claude Laborde, Eric Van Belle, Lars Sondergaard

October 31, 2017

Presentation TCT 2017

Viewpoint #1: PARTNER 2A and SURTAVI are Convincing TAVR is Preferred in ALL (Appropriate) Intermediate-Risk Patients

Presenter: Michael J. Reardon

October 30, 2017

Presentation TCT 2017

Featured Lecture: Transcatheter Aortic Valve Replacement With a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients : Complete 1-Year Outcomes from the SURTAVI Trial

Presenter: Martin B. Leon, Patrick T. O'Gara, Nicolas M. Van Mieghem

October 30, 2017

Presentation TCT 2016

Intermediate-Risk Studies II: Updates From SURTAVI

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Jeffrey J. Popma

October 30, 2016

Presentation TCT 2015

Status Update on Moderate-Risk TAVR RCTs 2: SURTAVI

Presenter: Martin B. Leon, Neil E. Moat, Patrick W. Serruys

October 11, 2015

News Conference News TCT 2015

Asian TAVR Registry Shows Good Procedural and Clinical Results

October 11, 2015

News Conference News TCT 2014

TCT Course Director Outlines Current TAVR Controversies

September 14, 2014

News Conference News TCT 2014

Lively Debate on Use of TAVR for Lower-Risk Patients

September 14, 2014

Presentation TCT 2014

Updates from SURTAVI in Intermediate-Risk Patients

Presenter: Martin B. Leon, Neil E. Moat, Ariel Finkelstein, Patrick W. Serruys

September 13, 2014

Presentation TCT 2013

Lessons Learned from PARTNER 2A and SURTAVI: Device Specificity, Trial Design, Endpoints, and Future Low-risk Studies

Presenter: Jodi Akin

October 30, 2013

News Conference News TCT 2013

Two Trials to Assess TAVR in Moderate-Risk Patients

October 30, 2013

Advertisement

TAVI Edges Out Surgery in 2-Year Costs for Low-risk Patients: PARTNER 3

SURTAVI: Five-Year Results From a Randomized Trial of TAVR vs. SAVR in Patients at Intermediate Surgical Risk

SURTAVI: Self-Expanding TAVI Valve Holds Up vs SAVR Through 5 Years

In-Person and Online: TCT to Showcase Imaging, Valves, DCBs, and More

TCT 125: TAVR with a Supra-Annular, Self-Expandable Valve in Intermediate Risk Patients: Follow-Up From the SURTAVI Randomized Trial and Continued Access Registry

SURTAVI: Two-Year Complete Results From a Randomized Trial of a Self-Expanding Transcatheter Heart Valve vs Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Intermediate Surgical Risk

SURTAVI Trial Critique and Unanswered Questions

SURTAVI: Topline Findings and Practice Implications

TCT 107: Transcatheter Aortic Valve Replacement With a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients: Complete 1-Year Outcomes From the SURTAVI Trial

TCT 39: Clinical Outcomes in SURTAVI Based on Revascularization Stratification

Viewpoint #1: PARTNER 2A and SURTAVI are Convincing TAVR is Preferred in ALL (Appropriate) Intermediate-Risk Patients

Featured Lecture: Transcatheter Aortic Valve Replacement With a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients : Complete 1-Year Outcomes from the SURTAVI Trial

Intermediate-Risk Studies II: Updates From SURTAVI

Status Update on Moderate-Risk TAVR RCTs 2: SURTAVI

Asian TAVR Registry Shows Good Procedural and Clinical Results

TCT Course Director Outlines Current TAVR Controversies

Lively Debate on Use of TAVR for Lower-Risk Patients

Updates from SURTAVI in Intermediate-Risk Patients

Lessons Learned from PARTNER 2A and SURTAVI: Device Specificity, Trial Design, Endpoints, and Future Low-risk Studies

Two Trials to Assess TAVR in Moderate-Risk Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content